AVOS Introduces Medicare Drug Benefit Outlooks Reports; Reports Analyze How Medicare Part D Will...

RALEIGH, N.C. -- The contact information in release should read:

AVOS Life Sciences
John Niedermayer, 919-848-2709
JNiedermayer@AvosLifeSciences.com
or
Maverick Marketing
Megan Haney, 919-459-2768
mhaney@maverickmarketing.com

sted:

AVOS Life Sciences
John Niedermayer,  919-459-2768
JNiedermayer@AvosLifeSciences.com
or
Maverick




				

				
				 
				


 Marketing
Megan Haney, 919-848-2709
mhaney@maverickmarketing.com

The corrected release reads:

AVOS INTRODUCES MEDICARE DRUG BENEFIT OUTLOOKS REPORTS; REPORTS ANALYZE HOW MEDICARE PART D WILL AFFECT THE PHARMACEUTICAL INDUSTRY

AVOS Life Sciences today announced the availability of Medicare Drug Benefit Outlooks (MDBO), a series of reports that analyze the impact of the Medicare Part D drug benefit on the pharmaceutical industry.

Part D was established by the Medicare Prescription Drug, Improvement and Modernization Act of 2003 and goes into effect January 1, 2006. Although this date is fast approaching, significant questions remain regarding the implications of the Part D drug benefit. MDBO examines the scenarios which may play out over the next three years at the product, drug portfolio and company level, taking into account variables such as Part D enrollment and cost containment strategies.

"This series was born from the need to understand the overall impact of this legislation by the investor community, as well as the pharmaceutical companies themselves," said Neil MacAllister, president of AVOS Life Sciences. "Due to the ambiguity surrounding actual implementation, entities have shied away from quantifying the potential impact of Part D. Our Medicare Drug Benefit Outlooks directly addresses this lack of analysis."

Unlike other analyses that stress the cost of the drug benefit to the taxpayer, MDBO projects revenue forecasts for individual products during the critical time period from 2006 to 2008. This approach allows AVOS to quantify the impact of the drug benefit on each major pharmaceutical company. The framework behind the reports includes the provisions set forth in the legislation, as well as therapeutic and public policy dimensions. As guidelines change and the legislation is implemented, AVOS will update the series to continue to provide competitive intelligence to the pharmaceutical and investment communities.

"Based upon our analysis, there are some clear winners - and some clear losers - in the Part D environment," continued MacAllister. "In the long term, this legislation has great potential to significantly alter the competitive landscape of the pharmaceutical industry."

About AVOS Life Sciences, LLC

AVOS is a boutique advisory and research products firm located in Raleigh, NC, and New York, NY. We specialize in developing and maintaining a leading-edge understanding of the evolving healthcare environment to help our clients position themselves to win in the future. Our unique capabilities are exemplified through AVOS Signals, a research product suite created to provide insight and guidance in product revenue forecasting, future stock performance and exposure to major industry trends. AVOS also offers consulting services where our experts work closely with client teams to respond to specific business needs. For additional information, please visit www.avoslifesciences.com.